Summary | |
---|---|
Symbol | SPHK2 |
Name | sphingosine kinase 2 |
Aliases | SK-2; SPK 2; SPK-2; sphingosine kinase type 2 |
Chromosomal Location | 19q13.33 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway |
Subcellular Location | Isoform 1: Cytoplasm. Membrane.; SUBCELLULAR LOCATION: Isoform 2: Lysosome membrane. |
Domain |
PF00781 Diacylglycerol kinase catalytic domain |
Function |
Catalyzes the phosphorylation of sphingosine to form sphingosine 1-phosphate (SPP), a lipid mediator with both intra- and extracellular functions. Also acts on D-erythro-dihydrosphingosine, D-erythro-sphingosine and L-threo-dihydrosphingosine. Binds phosphoinositides. |
Biological Process |
GO:0003376 sphingosine-1-phosphate signaling pathway GO:0006066 alcohol metabolic process GO:0006643 membrane lipid metabolic process GO:0006644 phospholipid metabolic process GO:0006665 sphingolipid metabolic process GO:0006668 sphinganine-1-phosphate metabolic process GO:0006669 sphinganine-1-phosphate biosynthetic process GO:0006670 sphingosine metabolic process GO:0007565 female pregnancy GO:0008654 phospholipid biosynthetic process GO:0019751 polyol metabolic process GO:0030148 sphingolipid biosynthetic process GO:0030258 lipid modification GO:0034311 diol metabolic process GO:0034312 diol biosynthetic process GO:0044283 small molecule biosynthetic process GO:0044706 multi-multicellular organism process GO:0046165 alcohol biosynthetic process GO:0046173 polyol biosynthetic process GO:0046467 membrane lipid biosynthetic process GO:0046512 sphingosine biosynthetic process GO:0046519 sphingoid metabolic process GO:0046520 sphingoid biosynthetic process GO:0046834 lipid phosphorylation GO:0090520 sphingolipid mediated signaling pathway GO:1901615 organic hydroxy compound metabolic process GO:1901617 organic hydroxy compound biosynthetic process |
Molecular Function |
GO:0001727 lipid kinase activity GO:0008481 sphinganine kinase activity GO:0017016 Ras GTPase binding GO:0017050 D-erythro-sphingosine kinase activity GO:0031267 small GTPase binding GO:0038036 sphingosine-1-phosphate receptor activity GO:0045125 bioactive lipid receptor activity GO:0051020 GTPase binding |
Cellular Component |
GO:0005765 lysosomal membrane GO:0098852 lytic vacuole membrane |
KEGG |
hsa04020 Calcium signaling pathway hsa04071 Sphingolipid signaling pathway hsa04370 VEGF signaling pathway hsa04666 Fc gamma R-mediated phagocytosis hsa00600 Sphingolipid metabolism hsa01100 Metabolic pathways |
Reactome |
R-HSA-1430728: Metabolism R-HSA-556833: Metabolism of lipids and lipoproteins R-HSA-1660661: Sphingolipid de novo biosynthesis R-HSA-428157: Sphingolipid metabolism |
Summary | |
---|---|
Symbol | SPHK2 |
Name | sphingosine kinase 2 |
Aliases | SK-2; SPK 2; SPK-2; sphingosine kinase type 2 |
Chromosomal Location | 19q13.33 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Literatures that report relations between SPHK2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells. |
Literatures describing the relation between SPHK2 and anti-tumor immunity in human cancer.
|
Summary | |
---|---|
Symbol | SPHK2 |
Name | sphingosine kinase 2 |
Aliases | SK-2; SPK 2; SPK-2; sphingosine kinase type 2 |
Chromosomal Location | 19q13.33 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets. |
> High-throughput Screening
[ TOP ]
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Statistical results of SPHK2 in screening data sets for detecting immune reponses.
|
Summary | |
---|---|
Symbol | SPHK2 |
Name | sphingosine kinase 2 |
Aliases | SK-2; SPK 2; SPK-2; sphingosine kinase type 2 |
Chromosomal Location | 19q13.33 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders |
Points in the above scatter plot represent the expression difference of SPHK2 in various data sets.
|
Points in the above scatter plot represent the mutation difference of SPHK2 in various data sets.
|
Summary | |
---|---|
Symbol | SPHK2 |
Name | sphingosine kinase 2 |
Aliases | SK-2; SPK 2; SPK-2; sphingosine kinase type 2 |
Chromosomal Location | 19q13.33 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of SPHK2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene. |
Summary | |
---|---|
Symbol | SPHK2 |
Name | sphingosine kinase 2 |
Aliases | SK-2; SPK 2; SPK-2; sphingosine kinase type 2 |
Chromosomal Location | 19q13.33 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of SPHK2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by SPHK2. > Immunoinhibitor > Immunostimulator > MHC molecule |
Summary | |
---|---|
Symbol | SPHK2 |
Name | sphingosine kinase 2 |
Aliases | SK-2; SPK 2; SPK-2; sphingosine kinase type 2 |
Chromosomal Location | 19q13.33 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of SPHK2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor |
Summary | |
---|---|
Symbol | SPHK2 |
Name | sphingosine kinase 2 |
Aliases | SK-2; SPK 2; SPK-2; sphingosine kinase type 2 |
Chromosomal Location | 19q13.33 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Distribution of SPHK2 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype |
Summary | |
---|---|
Symbol | SPHK2 |
Name | sphingosine kinase 2 |
Aliases | SK-2; SPK 2; SPK-2; sphingosine kinase type 2 |
Chromosomal Location | 19q13.33 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Associations between SPHK2 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade |